<DOC>
	<DOCNO>NCT02176512</DOCNO>
	<brief_summary>Study demonstrate bioequivalence telmisartan HCTZ administer fix dose combination comparison single unit formulation</brief_summary>
	<brief_title>Telmisartan/Hydrochlorothiazide ( HCTZ ) Fixed Dose Combination Compared Its Monocomponents Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Healthy subject determine result screen Signed write informed consent accordance GCP ( Good Clinical Practice ) local legislation Age ≥ 18 ≤ 45 year Broca ≥ 20 % ≤ + 20 % Any find medical examination ( include blood pressure , pulse rate ECG laboratory value ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder Supine blood pressure screen systolic ≤ 110 mmHg diastolic ≤ 60 mmHg History orthostatic hypotension , faint spell blackouts Hypersensitivity Telmisartan and/or HCTZ and/or related class drug History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Use drug might influence result trial ( ≤ 10 day prior administration trial ) Participation another trial investigational drug ( ≤ 2 month prior administration trial ) Smoker ( ≥ 10 cigarette ≥ 3 cigar ≥ 3 pipes/day ) Inability refrain smoke study day Known alcohol abuse Known drug abuse Blood donation ( ≤ 1 month prior administration ) Excessive physical activity ( ≤ 5 day prior administration ) For female subject : Pregnancy Positive pregnancy test No adequate contraception Inability maintain adequate contraception whole study period Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>